<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01520272</url>
  </required_header>
  <id_info>
    <org_study_id>999912021</org_study_id>
    <secondary_id>12-C-N021</secondary_id>
    <nct_id>NCT01520272</nct_id>
  </id_info>
  <brief_title>HPV Vaccine Effectiveness in Partially Vaccinated Girls in Uganda</brief_title>
  <official_title>Immunogenicity of Bivalent HPV Vaccine Among Partially Vaccinated Young Adolescent Girls in Uganda</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institutes of Health Clinical Center (CC)</source>
  <brief_summary>
    <textblock>
      Background:&#xD;
&#xD;
      - Cervical cancer is one of the leading causes of cancer death in women worldwide and in&#xD;
      Uganda. It is caused by the human papillomavirus (HPV). A vaccine against HPV was offered for&#xD;
      all 10-year-old girls in the Nakasongola district of Uganda from October 1, 2008, to October&#xD;
      31, 2009. The HPV vaccine requires three doses; however, some girls received only one or two&#xD;
      doses. Researchers want to compare vaccine immunogenicity in girls who received all three&#xD;
      doses with those who had only one or two doses.&#xD;
&#xD;
      Objectives:&#xD;
&#xD;
      - To examine the immunogenicity (antibody levels) of girls in Uganda who received only one,&#xD;
      two or three doses of HPV vaccine.&#xD;
&#xD;
      Eligibility:&#xD;
&#xD;
        -  Girls who will be at least 12 years old by October 31, 2011, and had at least one dose&#xD;
           of the HPV vaccine.&#xD;
&#xD;
        -  All participants will come from the Nakasongola district of Uganda.&#xD;
&#xD;
      Design:&#xD;
&#xD;
        -  Participants will have a physical exam and answer questions about their medical history&#xD;
           and HPV risk.&#xD;
&#xD;
        -  Participants will provide a single blood sample for testing.&#xD;
&#xD;
        -  Treatment and vaccines will not be provided as part of this study. Girls who did not&#xD;
           receive all three doses of the HPV vaccine will be given information about the nearest&#xD;
           health center. Health centers will provide the missed doses free of charge.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Background:&#xD;
&#xD;
      Recent experience with HPV vaccine implementation in low resource settings has suggested that&#xD;
      high vaccine coverage for all three doses could be achieved provided programs are planned&#xD;
      well and have full and complementary components in place. However, some locations experienced&#xD;
      substantial rates of partially vaccinated girls, those who received only one or two doses.&#xD;
      From the vaccine trial data published thus far, we know that the vaccines produce high levels&#xD;
      of type-specific anti-HPV antibodies which begin to stabilize past 24 months&#xD;
      post-vaccination. Without an immune correlate of protection, it is difficult to know whether&#xD;
      girls who received one or two vaccine doses will still experience the same benefit of&#xD;
      protection from HPV infection as those who received all three doses of vaccine.&#xD;
&#xD;
      Recent data from a trial of a two-dose regimen of vaccination of girls aged 9-13 years in&#xD;
      Vancouver, Canada have suggested that the immune response of girls who received only two&#xD;
      doses was non-inferior both to that of girls who received 3 doses and to that of adult women&#xD;
      aged 16-25 years who also received 3 doses. In a complementary study in Guanacaste, Costa&#xD;
      Rica, vaccine efficacy (defined as 12-month vaccine type-specific infection persistence)&#xD;
      among adult women who received either one or two doses of HPV vaccine as a part of the Phase&#xD;
      IIb clinical trials of Cervarix (GSK) was similar to women who received all three vaccines&#xD;
      doses.&#xD;
&#xD;
      This proposed study would provide additional insight into the immunogenicity of HPV vaccine&#xD;
      among partially vaccinated girls in Uganda, which could add supportive evidence in an African&#xD;
      adolescent population (currently not represented in any clinical studies of HPV vaccines) of&#xD;
      the immunological implications of receiving less than 3 doses of HPV vaccine.&#xD;
&#xD;
      Objective:&#xD;
&#xD;
      To investigate whether the anti-HPV 16 and/or anti-HPV-18 immune responses elicited by the&#xD;
      bivalent vaccine for girls who received one dose and those who received two doses are similar&#xD;
      at greater than or equal to 24 months (after last dose) to girls who received all three doses&#xD;
      of bivalent HPV vaccine.&#xD;
&#xD;
      Eligibility:&#xD;
&#xD;
      Girls who received at least one dose of the HPV vaccine, 12-20 years of old, in apparent good&#xD;
      general health.&#xD;
&#xD;
      Design:&#xD;
&#xD;
      This is a cross-sectional immunogenicity study with three groups:&#xD;
&#xD;
      Group 1 - 200 girls who received only one dose of HPV vaccine as a part of the PATH-UNEPI HPV&#xD;
      vaccine demonstration project;&#xD;
&#xD;
      Group 2 - 200 girls who received only two doses of HPV vaccine as a part of the PATH-UNEPI&#xD;
&#xD;
      HPV vaccine demonstration project; and&#xD;
&#xD;
      Group 3 - 200 girls who received all three doses of HPV vaccine as a part of the PATH-UNEPI&#xD;
      HPV vaccine demonstration project.&#xD;
&#xD;
      This study will enroll girls (by group) within one district of Uganda from an HPV vaccine&#xD;
      registry maintained by the district.&#xD;
&#xD;
      Antibody level will be parameterized as the geometric mean titre of serum antibody to HPV&#xD;
      types 16 and/or 18 at greater than or equal to 24 months after last dose of vaccine. Titres&#xD;
      will be measured using the polyclonal Direct VLP ELISA.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2, 2012</start_date>
  <completion_date>June 28, 2017</completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>HPV Immunogenicity</measure>
    <time_frame>Ongoing</time_frame>
  </primary_outcome>
  <enrollment type="Actual">376</enrollment>
  <condition>HPV16 Anitbody Levels Post Vaccination</condition>
  <condition>HPV18 Antibody Levels Post Vaccination</condition>
  <eligibility>
    <criteria>
      <textblock>
        -  INCLUSION CRITERIA:&#xD;
&#xD;
        The following inclusion criteria will be reviewed at the time of enrollment, and where&#xD;
        noted, confirmed at the clinic visit, immediately prior to blood draw:&#xD;
&#xD;
          -  Subject is aged 12-17 years as of August 31, 2011.&#xD;
&#xD;
          -  Subject received at least one dose of HPV vaccine, Cervarix (GSK, UK), from October 1,&#xD;
             2008 through October 31, 2009 as a part of the PATH HPV vaccine demonstration project&#xD;
             in Nakasongola, Uganda.&#xD;
&#xD;
          -  Signed and dated informed written consent form (with both parent and subject s&#xD;
             signatures) received (confirmed at clinic visit).&#xD;
&#xD;
          -  Subject is afebrile, in good apparent health (confirmed at clinic visit).&#xD;
&#xD;
          -  Subject assents to participate (confirmed at clinic visit).&#xD;
&#xD;
          -  Subject is able to comply with the study protocol (confirmed at clinic visit).&#xD;
&#xD;
          -  Subject plans to stay in Nakasongola for the duration of enrolment, which is expected&#xD;
             to be about week between signed consent and blood draw.&#xD;
&#xD;
        EXCLUSION CRITERIA:&#xD;
&#xD;
        The following exclusion criteria will be reviewed at the time of enrollment, and where&#xD;
        noted, confirmed at the clinic visit.&#xD;
&#xD;
          -  Prior HPV vaccination outside the PATH HPV vaccine demonstration project period.&#xD;
&#xD;
          -  Subject is known to be pregnant or lactating at the time of the scheduled blood draw&#xD;
             (confirmed at clinic visit).&#xD;
&#xD;
          -  Subject has an apparent moderate or severe acute illness or has fever (confirmed at&#xD;
             clinic visit).&#xD;
&#xD;
          -  Clinical history of bleeding disorders such as haemophilia, thrombocytopenia, or&#xD;
             anticoagulant therapy.&#xD;
&#xD;
          -  Investigational drug or investigational vaccine or licensed vaccine administered&#xD;
             during the period from 30 days before the date of the scheduled blood draw (confirmed&#xD;
             at clinic visit).&#xD;
&#xD;
          -  Subject receives immunoglobulins and/or any blood products during the period from 30&#xD;
             days before the date of the scheduled blood draw (confirmed at clinic visit).&#xD;
&#xD;
          -  Subject or subject s parents refused to sign written consent.&#xD;
&#xD;
          -  Subject does not assent at the time of the blood draw.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>20 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Allan Hildesheim, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Cancer Institute (NCI)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>District of Nakasangola</name>
      <address>
        <city>Kampala</city>
        <country>Uganda</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Uganda</country>
  </location_countries>
  <reference>
    <citation>Banura C, Mirembe FM, Katahoire AR, Namujju PB, Mbonye AK, Wabwire FM. Epidemiology of HPV genotypes in Uganda and the role of the current preventive vaccines: A systematic review. Infect Agent Cancer. 2011 Jul 12;6(1):11. doi: 10.1186/1750-9378-6-11.</citation>
    <PMID>21749691</PMID>
  </reference>
  <reference>
    <citation>Block SL, Nolan T, Sattler C, Barr E, Giacoletti KE, Marchant CD, Castellsagu√© X, Rusche SA, Lukac S, Bryan JT, Cavanaugh PF Jr, Reisinger KS; Protocol 016 Study Group. Comparison of the immunogenicity and reactogenicity of a prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in male and female adolescents and young adult women. Pediatrics. 2006 Nov;118(5):2135-45.</citation>
    <PMID>17079588</PMID>
  </reference>
  <reference>
    <citation>Centers for Disease Control and Prevention (CDC). National, state, and local area vaccination coverage among adolescents aged 13-17 years --- United States, 2009. MMWR Morb Mortal Wkly Rep. 2010 Aug 20;59(32):1018-23.</citation>
    <PMID>20724968</PMID>
  </reference>
  <verification_date>June 28, 2017</verification_date>
  <study_first_submitted>January 26, 2012</study_first_submitted>
  <study_first_submitted_qc>January 26, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2012</study_first_posted>
  <last_update_submitted>April 4, 2018</last_update_submitted>
  <last_update_submitted_qc>April 4, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 5, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HPV18 Immunogenicity</keyword>
  <keyword>HPV16 Immunogenicity</keyword>
  <keyword>Bivalent HPV16/18 Vaccine</keyword>
  <keyword>Less than 3 Dosed of the Bivalent HPV Vaccine</keyword>
  <keyword>HP Vaccine</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

